A calibrated automated thrombogram is not affected by the turbidity of platelet and cell preparations because the measurement is based on fluorescence. To examine conditions that mimic the physiological state, we investigated thrombograms that show thrombin generation on tissue factor (TF)-bearing cells. An increase in the number of J82 cells did not affect the endogenous thrombin potential (ETP) of normal plasma, although the lag time (LT), the peak height, and the time to peak (ttPeak) did depend on cell concentration. When 5 parameters of coagulation factor-deficient plasmas were plotted on a radar graph, the thrombogram pattern of factor XI (FXI)-deficient plasma became slightly reduced. The thrombogram did not improve when washed normal platelets or washed normal platelets with adenosine diphosphate (ADP) were added. FVII-depleted plasma, FVIIIdeficient plasma, and FIX-deficient plasma showed remarkably reduced peak heights, ttPeaks, and times to the end of thrombin generation (start tails). The thrombogram of FVIIdepleted plasma was characterized by a remarkably prolonged LT, unlike the patterns of FVIII-or FIX-deficient plasma and FXI-depleted plasma. The ETP of FVIII-and FIX-deficient plasma, but not FVII-depleted plasma, improved significantly upon addition of washed normal platelets or washed normal platelets with ADP. The thrombograms of coagulation factordeficient plasma containing TF-bearing cells differed from those for recombinant TF and phospholipid in the liquid phase. We suggest that thrombograms using TF-bearing cells can be a useful ex vivo test, because this experimental model may be analogous to most coagulation processes in vivo.
INTRODUCTION
Blood coagulation tests have generally been performed by determining both the activated partial thromboplastin time to test intrinsic-pathway function according to the waterfallcascade sequence and the prothrombin time to test extrinsicpathway function. Although these coagulation tests are useful, they do not always accurately reflect clinical symptoms because they are carried out under nonphysiological conditions [1] [2] . It has been thought that factor VII (FVII) and activated FVII (FVIIa) bind in vivo to tissue factor (TF) derived from TF-bearing cells on damaged endothelium and that this complex activates FX and FIX to generate abundant thrombin via amplification of the coagulation cascade [3, 4] .
The calibrated automated thrombogram (CAT), which measures time-dependent thrombin generation with trace tissue thromboplastin without defibrination treatment, was developed to assess coagulation mechanisms relevant to abnormal hemostasis [5] . The CAT is not influenced by turbidity because it measures fluorescence from a thrombincleaved substrate [6] . Although the CAT has been reported to be useful for assessing a thrombotic tendency [7] [8] [9] , there are no reports of its use as an ex vivo test to assess blood coagulation defects in assays using TF-bearing cells.
To examine thrombin generation under conditions that mimic the physiological states of patients with coagulation defects, we carried out CAT assays and generated thrombograms to analyze thrombin generation by normal plasma, FXI-depleted plasma, FIX-deficient plasma, FX-deficient plasma, FVIII-deficient plasma, and FVII-depleted plasma by using cells from the bladder carcinoma cell line J82,
40
Takamiya and Sakata which expresses TF at high density [10] . We also carried out CAT assays with washed normal platelets, with and without added adenosine diphosphate (ADP).
MATERIALS AND METHODS
Samples of peripheral venous blood were drawn from 20 healthy volunteers who had not taken any drugs for at least a week and were collected into a one-tenth volume of a 3.2% trisodium citrate solution (wt/vol). Plasma was obtained by immediate centrifugation of the samples at room temperature for 15 minutes at 3000 rpm; the individual plasma fractions were combined to make a pool of normal plasma. FVII-depleted plasma was prepared from the normal pooled plasma by immunoaffinity chromatography with insolubilized antihuman FVII antibody [11] , and FXIdepleted plasma was prepared by immunoaffinity chromatography with insolubilzed monoclonal antihuman FXI antibody (kindly provided by Dr. Yutaka Komiyama, Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Osaka, Japan). FX-deficient plasma, FIX-deficient plasma, and FVIII-deficient plasma were purchased from Sysmex (Kobe, Japan).
The bladder carcinoma cell line J82 was kindly provided by Prof. Katsusuke Naito, Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan. The cells were cultured at 37ºC in a 5%-CO 2 atmosphere in Dulbecco Modified Eagle Medium supplemented with fetal bovine serum (10% by volume), 2 mmol/L L-glutamine, 10 mmol/L HEPES (pH 7.2), 100 units/mL penicillin G, and 100 µg/mL streptomycin. For CAT, J82 cells were cultured overnight in medium-containing wells of 96-well microplates at cell concentrations of 1, 10, 100, and 1000 cells/well. We washed the cells twice with 0.01 mol/L TrisHCl buffer containing 0.15 mol/L NaCl (TBS) and measured thrombin generation by adding 80 µL of plasma, 20 µL of HEPES buffer, and 20 µL of 2 mmol/L solution of a fluorogenic substrate (Z-GGR-AMC; Calbiochem, Darmstadt, Germany) containing 2 mmol/L CaCl 2 to the washed cells in the 96-well microplates and then monitoring the fluorescence with a fluorometer (Fluoroskan Ascent; Thermo Fisher Scientific, Waltham, MA, USA). Corn trypsin inhibitor (final concentration, 60 µg/mL; Calbiochem) was added to the plasma samples to eliminate contact factor activation. As a control, we used 20 µL of Thrombin Calibrator (Synapse, Maastricht, the Netherlands) instead of HEPES buffer. After measuring the fluorescence, we calculated 5 thrombin-generation parameters with Thrombinoscope software (Synapse): endogenous thrombin potential (ETP), peak height, lag time (LT), time to peak (ttPeak), and time to the end of thrombin generation (start tail) (Figure 1 ). In addition, to measure the effect of platelets on thrombin generation, we measured thrombograms by adding 80 µL of plasma sample and either 10 µL of washed platelets (final concentration, 5 × 10 4 /µL) plus 10 µL HEPES buffer or 10 µL washed platelets plus 10 µL ADP (final concentration, 0.2 µmol/L; Sigma-Aldrich, St. Louis, MO, USA) instead of the HEPES buffer. We isolated normal platelets from platelet-rich plasma collected from healthy volunteers via gel filtration on a Sepharose 4B column (2.5 × 40 cm) at a flow rate of 1. 
RESULTS
In normal plasma, J82 cells shortened the LT and the ttPeak in a concentration-dependent manner but did not reduce the ETP and the peak height. The LT and ttPeak were remarkably prolonged without the cells (Figure 2) . The J82 cells did not hydrolyze the fluorogenic substrate directly in the absence of plasma, even when the Ca 2+ ion was present (data not shown).
We measured thrombin generation of normal plasma and coagulation factor-deficient plasma after overnight culture of J82 cells adjusted to a concentration of 100 cells/well. FX-deficient plasma generated less thrombin, and the thrombogram was inaccurate. The LT of FVII-depleted plasma was remarkably prolonged compared with normal plasma and other coagulation factor-deficient plasmas. The ETP of FIX-deficient plasma apparently decreased compared with normal plasma. The peak heights of FIX-deficient plasma, FVIII-deficient plasma, and FVII-depleted plasma were significantly reduced compared with normal plasma. Both the ttPeak and the start tail of FIX-deficient plasma, FVIII-deficient plasma, and FVII-depleted plasma were apparently prolonged compared with normal plasma (Table) . When the values of the measurement parameters for these results were normalized to those for normal plasma (ie, expressed as a ratio to the values for normal plasma) and represented as radar graphs, the values for 4 of the parameters of FXI-depleted plasma demonstrated slight reductions, but the ETP value was unchanged. Both FVIII-deficient plasma and FIX-deficient plasma showed similar patterns in that the peak height, the ttPeak, and the start tail were remarkably reduced. On the other hand, the LT, peak height, ttPeak, and start tail values were remarkably reduced for FVII-depleted plasma ( Figure 3) . Next, we added washed normal platelets or washed normal platelets with ADP and measured the thrombogram in microplate wells in the presence of washed J82 cells. Thrombograms of normal plasma and washed normal platelets (both with and without added ADP) hardly changed compared with assays carried out with only J82 cells. Addition of washed platelets or washed platelets plus ADP to FXI-depleted plasma also had little influence on any of the parameter values. The ETP values of FIX-deficient plasma and FVIII-deficient plasma apparently increased when platelets were added, with or without ADP. The peak heights of FVII-depleted plasma, FIX-deficient plasma, and FVIII-deficient plasma increased in the presence of platelets with or without ADP, compared with the peak heights of only J82 cells (Figure 4) .
The TM reading in J82 cells was 700 mg/10 6 cells by enzyme-linked immunosorbent assay. Immunohistochemical techniques for detecting TM in J82 cells indicated that TM was present diffusely throughout the cytoplasm.
DISCUSSION
Homeostasis in vivo requires TF-bearing cells and activated platelets at the sites of vascular injury; however, for reasons of convenience, both the activated partial thromboplastin time and the prothrombin time have traditionally been evaluated in liquid-phase reactions under nonphysiological conditions. Such tests cannot take into account physiologically relevant anticoagulants, such as TM on the endothelium surface, which inhibits the thrombin generated during the coagulation process. Hemker et al reported that the addition of activated protein C and TM to plasma inhibited the generation of thrombin with the CAT [5] . TM was demonstrated in human urinary bladder cells and in the BOY cell line, which was generated from transitional carcinoma cells of the urinary bladder [12] . We also confirmed the existence of TM in J82 cells, which are carcinoma cells of the urinary bladder, by both enzyme immunoassay and immunohistochemical staining. J82 is considered a useful model for ex vivo coagulation testing because it mimics the physiological coagulation system by assembling a functional prothrombinase complex on the cell surface. The interactions between FVII and J82 cells have been studied extensively by Kisiel's group [13] [14] [15] . J82 cells express TF on >90% of the cells without any stimulation [16] . Although some tumor cells are known to directly convert prothrombin to thrombin or FX to FXa [17] , J82 cells have been shown to convert FX to FXa via the FVII/FVIIa-TF complex pathway [14, 15] .
FX-deficient plasma did not generate thrombin in the presence of J82 cells, although a trace peak height was visible. It was not clear whether FX-deficient plasma lacked FX completely, so this nominal peak may have been an artifact.
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Takamiya and Sakata Increasing the concentration of J82 cells had little effect on the ETP, although the LT depended on the concentration of the cells. When 5 parameters of coagulation factor-deficient plasma were presented on radar graphs, all of the parameters of FXI-depleted plasma except ETP were slightly reduced compared with normal plasma. We also demonstrated that thrombin generation by FXI-depleted plasma was not amplified in the presence of either platelets or activated platelets. FXI binds specifically to high-affinity sites on leucine-rich repeats of glycoprotein 1b (GP1b) located on the surface of stimulated platelets, and FXI is activated by thrombin binding to an anionic region on GP1b [18] . The radar graphs for FVII-depleted plasma, FVIII-deficient plasma, and FIX-deficient plasma showed similar patterns except for the LT. The thrombogram of FVII-depleted plasma had a remarkably prolonged LT. Neither the LT nor the ETP of FVII-depleted plasma was improved by the addition of platelets or activated platelets. Barnett et al reported that a patient with FVII-deficient plasma (<1% of the normal level) had an ETP and peak height that were significantly decreased and a slightly delayed ttPeak. Platelet-rich plasma from this patient significantly increased the ETP and peak height and prolonged the ttPeak [19] . Giansily-Blaizot et al reported that FVII-depleted plasma treated by defibrination did not generate thrombin, but the ETP and peak height of plasma with 1% FVII were 32% and 28% of normal control values, respectively [20] . We thought that this result reflected the difference between coagulation in the liquid phase and that on TF-bearing cells. Chantarangkul et al have suggested that ETP measurement with low levels of TF may be helpful for assessing thrombin generation in hemophilia patients [8] . Dargaud et al reported that the ETP for severe hemophilia A (<1%) and severe hemophilia B (<1%) was 3% to 49% of normal controls when measurements were made with 4 ºmol/L phosphatide and 1 pmol/L TF [21] . The ETP, peak height, and ttPeak values for plasma from hemophilia patients were reported to apparently decrease, but the LT was within the normal range [22] . Our results with TF-bearing cells were approximately similar to previous results obtained with thrombography. The thrombograms for FVIII-and FIXdeficient plasmas showed that platelets or activated platelets amplified the ETP remarkably in these plasmas. The ETP in the thrombogram for FIX-deficient plasma increased more in the presence of washed platelets plus ADP than in the presence of washed platelets without ADP. Siegemund et al reported that the difference between hemophilia A and B in thrombin generation might be attributed to the role of platelets in the assembly of the tenase complex on the platelet surface [23] . Dargaud et al reported that thrombin generation was retarded in the presence of intact platelets because unactivated platelets do not undergo phospholipid scrambling, which leads to surface exposure of phosphatidylserine [22] . We supposed that trace levels of FVIII and FIX, which might have been present in the deficient plasmas, increased the ETP in the presence of activated platelets, because FVIIIa and FIXa can amplify coagulation in vivo on activated platelets. Thrombograms for FVIIdepleted plasma were not affected by the presence of activated or unactivated platelets, probably because FVIIa at low levels does not act at the surface of the activated platelet.
The results obtained for thrombograms for coagulation factor-deficient plasmas with TF-bearing cells were somewhat different from results obtained with recombinant TF and phospholipid in the liquid phase. We suggest that thrombograms using TF-bearing cells can be a useful ex vivo test, because this experimental model may be analogous to most coagulation processes in vivo.
